Latest Headlines

  1. BullFrog AI To Present bfPREP At The AI Drug Discovery & Development Summit 2025 11/12/2025

    BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that it will present a technical talk at the upcoming AI Drug Discovery & Development Summit 2025, taking place November 18–20, 2025, in Boston, Massachusetts.

  2. BenchSci And Mila Partner To Advance AI For Biological Inference And Accelerate Drug Discovery 11/12/2025

    BenchSci, a leading provider of AI software for biopharma research and development, and Mila - Quebec Artificial Intelligence Institute, one of the world’s premier AI research centers, today announced a multi-year partnership to advance the use of artificial intelligence for biological inference.

  3. BostonGene And Kyoto University Partner To Accelerate Precision Drug Development 11/12/2025

    BostonGene, developer of the leading AI foundation model for cancer and the immune system, and Kyoto University, a research institution known for its groundbreaking advancements in medicine and science announced today a research collaboration to develop advanced biological signatures to enhance targeted treatment strategies for patients with esophageal squamous cell carcinoma (ESCC).

  4. Avenzo Therapeutics Granted Fast Track Designation For AVZO-1418, A Potential Best-In-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, For The Treatment Of Patients With EGFR-Mutated TKI-Pretreated NSCLC 11/10/2025

    Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the U.S. Food and Drug Administration (FDA) granted Fast Track designation to AVZO-1418 (DB-1418), a potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate (BsADC).

  5. Why Creative Biolabs Is Betting On AI-Driven Chemical Synthesis To Accelerate Drug Innovation 11/10/2025

    Within the research and development (R&D) sphere, Creative Biolabs serves its clients across all the important areas of pharmaceutical development—right from molecular design to the complex drug substance preparation.

  6. Insilico And Lilly Enter A Research & Licensing Collaboration To Advance AI-Driven Drug Discovery 11/10/2025

    Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced a research collaboration with Eli Lilly ("Lilly") that the two parties will combine Insilico's state-of-the-art Pharma.AI platforms with Lilly's development and disease expertise to jointly discover and advance innovative therapies.

  7. Harbour BioMed And Evinova China Announce Strategic AI Collaboration To Accelerate AI-Enabled Drug Development 11/7/2025

    Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Evinova, a global health-tech company accelerating the delivery of better health outcomes by propelling the life sciences sector forward in digital health, announced a strategic collaboration in artificial intelligence (AI).

  8. Abzena And Mabqi Announce Strategic Partnership To Offer Integrated Discovery Through Development Solution 11/6/2025

    This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution.

  9. MavriX Bio Announces First Patient Dosed In ASCEND-AS Trial Of MVX-220, Investigational Gene Therapy For Angelman Syndrome 11/6/2025

    MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the first patient has been dosed in the Phase 1/2 ASCEND-AS clinical trial of MVX-220, an investigational gene therapy for AS.

  10. Arcturis And Royal Berkshire NHS Foundation Trust Enter Strategic Partnership 11/5/2025

    Arcturis, the UK leader in the curation of deep, multi-modal data to support the development of precision medicines, announces the continuing expansion of its Real-World Data Network (”RWD Network”) through the signing of a multi-year strategic partnership with Royal Berkshire NHS Foundation Trust (“Royal Berkshire”).